Clinical Trials in Austin

Showing 441-460 of 15,205 trials

I.V. Selonabant in Healthy Adult Subjects

NCT07211607

This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous Selonabant in Healthy Adult Subjects Aged 18 to 30 Years

Healthy Volunteers

Anebulo Pharmaceuticals40 participantsStarted Sep 2025

Austin, Texas, United States

COMPLETEDPhase 2< 1 mile

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

NCT02477020

The purpose of this study is to evaluate the efficacy, safety and tolerability of TAK-063 compared with placebo in treatment of acutely exacerbated schizophrenia.

Schizophrenia

Takeda164 participantsStarted Jul 2015

Springdale, Alaska, United States • Culver City, California, United States • Lemon Grove, California, United States +12 more locations

Active Not RecruitingPhase 3< 1 mile

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

NCT05171647

This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).

Non-Hodgkin Lymphoma

Hoffmann-La Roche208 participantsStarted Apr 2022

Duarte, California, United States • Chesterfield, Missouri, United States • Austin, Texas, United States +49 more locations

I.V. Selonabant in Healthy Adult Subjects

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Find Trials by Condition in Austin

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Radiprodil in Participants With Hepatic Impairment

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)

CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

IKS014 in Advanced Solid Tumors That Express HER2

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma